Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry

Cancer Immunology, Immunotherapy

Volumn 62, Issue 5, 2013, Pages 829-837

  Soliman, Hatem ^a   Rawal, Bhupendra ^a   Fulp, Jimmy ^a   Lee, Ji Hyun ^a   Lopez, Alexis ^a   Bui, Marylin M ^a   Khalil, Farah ^a   Antonia, Scott ^a   Yfantis, Harris G ^b   Lee, Dong H ^b   Dorsey, Tiffany H ^c   Ambs, Stefan ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

3 dioxygenase; Breast cancer; Immunohistochemistry; Immunotherapy; Indoleamine 2

Indexed keywords

CD11B ANTIGEN; CD8 ANTIGEN; CYCLOOXYGENASE 2; CYTOKERATIN 5; CYTOKERATIN 6; ESTROGEN RECEPTOR; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; PROGESTERONE RECEPTOR; PROTEIN KINASE B; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SPECIFIC SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SECTION; UNIVARIATE ANALYSIS;

BREAST NEOPLASMS; CYCLOOXYGENASE 2; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGRESSION ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877831917     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1393-y     Document Type: Article

References (21)

1. Prendergast GC (2008) Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27(28):3889-3900
2. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281(5380):1191-1193
3. Mellor AL, Munn D, Chandler P, Keskin D, Johnson T, Marshall B, Jhaver K, Baban B (2003) Tryptophan catabolism and T cell responses. Adv Exp Med Biol 527:27-35
4. Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev 4(10):762-774
5. Munn DH (2006) Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 18(2):220-225
6. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P (2002) T cell apoptosis by tryptophan catabolism. Cell Death Differ 9(10):1069-1077
7. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 196(4):459-468
8. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL (2005) GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22(5):633-642
9. Ge K, Duhadaway J, Sakamuro D, Wechsler-Reya R, Reynolds C, Prendergast GC (2000) Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int J Cancer 85(3):376-383
10. Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R, Sakamuro D, Nelson P, Malkowicz SB, Tomaszewski J, Prendergast GC (2000) Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int J Cancer 86(2):155-161
11. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, Margreiter R, Konigsrainer A, Fuchs D, Amberger A (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12(4):1144-1151
12. Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M (2005) Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11(16):6030-6039
13. Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S, Nagasaka T, Takikawa O, Kikkawa F (2006) Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 95(11):1555-1561. doi: 10.1038/sj.bjc.6603477
14. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11(3):312-319
15. Yu J, Sun J, Wang SE, Li H, Cao S, Cong Y, Liu J, Ren X (2011) Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis. Clin Dev Immunol 2011:469135. doi: 10.1155/2011/469135
16. Jacquemier J, Bertucci F, Finetti P, Esterni B, Charafe-Jauffret E, Thibult ML, Houvenaeghel G, Van den Eynde B, Birnbaum D, Olive D, Xerri L (2011) High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int J Cancer Journal international du cancer. doi: 10.1002/ijc.25979
17. Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD, Ying L, Pfiester CM, Yfantis HG, Cottrell JR, Lee DH, Remaley AT, Hofseth LJ, Wink DA, Ambs S (2007) Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 120(4):796-805. doi: 10.1002/ijc.22336
18. Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S (2006) Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98(13):911-919. doi: 10.1093/jnci/djj245
19. Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, Martin DN, Switzer CH, Hudson RS, Wink DA, Lee DH, Stephens RM, Ambs S (2010) Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest 120(11):3843-3854. doi: 10.1172/JCI42059
20. Thomas SR, Terentis AC, Cai H, Takikawa O, Levina A, Lay PA, Freewan M, Stocker R (2007) Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J Biol Chem 282(33):23778-23787. doi: 10.1074/jbc.M700669200
21. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, Lang RA, Pollard JW (2009) A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 4(8):e6562. doi: 10.1371/journal.pone.0006562